Compare Corning Incorporated (GLW) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Inovio Pharmaceuticals Inc — how do they compare? Corning Incorporated trades at $156.36 (market cap $150.10B), while Inovio Pharmaceuticals Inc trades at $1.14 (market cap $96.26M). The key difference: Corning Incorporated is far larger — about 1559.3× Inovio Pharmaceuticals Inc's market cap, and Corning Incorporated pays a 0.64% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GLW | INO | |
|---|---|---|
Market Cap | $150.10B | $96.26M |
Sector | Technology | Health |
52-Week High | $255.79 | $2.87 |
52-Week Low | $52.97 | $1.05 |
Enterprise Value | $158.27B | $67.27M |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLW is trading at $156.59, down 16.57% over 24 hours, reflecting a significant pullback from recent highs. The stock shows bearish technical signals but maintains strong fundamentals with revenue growth to $15.63 billion in 2025 and net income of $1.60 billion. Recent earnings beats and analyst optimism around AI-driven optical communication demand provide a positive backdrop despite near-term volatility.
The outlook for GLW is cautiously optimistic, with a consensus price target of $210.10 implying substantial upside. Key opportunities include partnerships with NVIDIA and Amazon in AI infrastructure, while risks involve high valuation multiples and sensitivity to tech sector sentiment. Long-term growth in 5G and automotive glass supports the investment case.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
